Conclusion

In this review, we demonstrated that in critically ill patients enteral immunomodulatory diet might be benefitial compared to standard formula specially in septic and ARDS conditions. However, the long-term benefits of this diet on clinical outcomes and mortality needs to be tested in well-designed trials with longer follow-up.